Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Respiratory

Thumbnail
February 16, 2021

Covid-19 could scupper Glaxo’s next vaccine push

Thumbnail
February 02, 2021

Tezepelumab’s non-eosinophilic edge emerges

Article image
Vantage logo
January 15, 2021

Kinaset takes a sledgehammer to an asthma conundrum

The nascent company hopes to prove that its inhaled pan-Jak is best in class.

Article image
Vantage logo
January 06, 2021

US FDA approval tracker: December

Article image
Vantage logo
December 22, 2020

Source flop raises tezepelumab questions

Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.

Article image
Vantage logo
December 18, 2020

First-quarter catalysts for the smaller players

Important data releases are on the cards for Rhythm, Wave and Supernus, among others.

Article image
Vantage logo
December 04, 2020

Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline

Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.

Article image
Vantage logo
November 30, 2020

Kinaset up for a tough ride with inhaled Jak focus

Article image
Vantage logo
November 10, 2020

Amgen finally Navigates a win

The asthma project tezepelumab shows an effect in both eosinophilic and non-eosinophilic patients.

Article image
Vantage logo
October 29, 2020

Glaxo’s latest asthma cull puts Astra in the spotlight

Article image
Vantage logo
October 14, 2020

Ionis joins the inhaled cystic fibrosis therapy race

Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.